Geoffrey Guittard

8PUBLICATIONS
38CO-AUTHORS
Haematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 20, 2024
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis.

Anne-Charlotte Le Floch, Caroline Imbert, Nicolas Boucherit

|Jul 02, 2024
DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing.

Vladimir Laletin, Pierre-Louis Bernard, Camille Montersino

|May 25, 2023
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.

Clémence Demerlé, Laurent Gorvel, Marielle Mello

|May 22, 2023
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets.

Vladimir Laletin, Pierre-Louis Bernard, Cathy Costa da Silva

|Jul 27, 2022
CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression.

Laurys Boudin, Alexandre De Nonneville, Pascal Finetti

|May 19, 2022
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity.

Pierre-Louis Bernard, Rebecca Delconte, Sonia Pastor

Pageof 2

Frequent Collaborators

5 joint publications

Jacques Nunes

3 joint publications

Daniel Olive

2 joint publications

Laurent Gorvel

1 joint publications

Mathieu Frechin